Glucagon-like peptide-1 and glucagon-like peptide-2

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 18, Issue 4, 2004, Pages 531-554

  Baggio, Laurie L ^a   Drucker, Daniel J ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Apoptosis; Cell proliferation; Diabetes; food intake; Insulin secretion; Intestinal disease; Obesity

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ANTIDIABETIC AGENT; DEXTRAN SULFATE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; EXENDIN 4; EXENDIN[9-39]; FLUOROURACIL; GLICENTIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR BLOCKING AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR STIMULATING AGENT; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; INDOMETACIN; INSULIN; IRINOTECAN; LIRAGLUTIDE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYNTOMODULIN; STREPTOZOCIN; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; PEPTIDE; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; ENDOCRINE CELL; ENZYME INHIBITION; FEEDING; FEEDING BEHAVIOR; FOOD INTAKE; GASTROINTESTINAL DISEASE; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HORMONAL REGULATION; HORMONE ACTION; HORMONE INHIBITION; HORMONE METABOLISM; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTESTINE CRYPT; INTESTINE INJURY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; SINGLE DRUG DOSE; STOMACH ACID SECRETION; STOMACH EMPTYING; SUSTAINED RELEASE FORMULATION; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR FUNCTION; METABOLISM; NERVOUS SYSTEM FUNCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION;

ANIMALS; CARDIOVASCULAR PHYSIOLOGY; DIABETES MELLITUS, TYPE 2; FEEDING BEHAVIOR; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; GLUCOSE; HUMANS; NERVOUS SYSTEM PHYSIOLOGY; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN PRECURSORS;

EID: 8344287000     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2004.08.001     Document Type: Review

References (210)

1. D.J. Drucker Biological actions and therapeutic potential of the glucagon-like peptides Gastroenterology 122 2002 531-544
2. P.L. Brubaker & D.J. Drucker Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 145 2004 2653-2659
3. J.L. Estall & D.J. Drucker Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling J Nutr 133 2003 3708-3711
4. Y. Wei & S. Mojsov Distribution of GLP-1 and PACAP receptors in human tissues Acta Physiol Scand 157 1996 355-357
5. I. Merchenthaler M. Lane & P. Shughrue Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system J Comp Neurol 403 1999 261-280
6. F. Satoh S.A. Beak C.J. Small et al. Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: Lack of coupling to either stimulation or inhibition of adenylyl cyclase Endocrinology 141 2000 1301-1309
7. D.J. Drucker & S. Asa Glucagon gene expression in vertebrate brain J Biol Chem 263 1988 13475-13478
8. U. Novak A. Wilks G. Buell et al. Identical mRNA for preproglucagon in pancreas and gut Eur J Biochem 164 1987 553-558
9. B. Schjoldager P.E. Mortensen J. Myhre et al. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions Dig Dis Sci 34 1989 1411-1419
10. M.A. Cohen S.M. Ellis C.W. Le Roux et al. Oxyntomodulin suppresses appetite and reduces food intake in humans J Clin Endocrinol Metab 88 2003 4696-4701
11. C.L. Dakin I. Gunn C.J. Small et al. Oxyntomodulin inhibits food intake in the rat Endocrinology 142 2001 4244-4250
12. N.G. Seidah & M. Chretien Proprotein and prohormone convertases: A family of subtilases generating diverse bioactive polypeptides Brain Res 848 1999 45-62
13. S. Dhanvantari N.G. Seidah & P.L. Brubaker Role of prohormone convertases in the tissue-specific processing of proglucagon Mol Endocrinol 10 1996 342-355
14. M. Furuta H. Yano A. Zhou et al. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2 Proc Natl Acad Sci USA 94 1999 6646-6651
15. C. Orskov J.J. Holst S. Knuhtsen et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas Endocrinology 119 1986 1467-1475
16. K. Sjolund G. Sanden R. Hakanson et al. Endocrine cells in human intestine: An immunocytochemical study Gastroenterology 85 1983 1120-1130
17. P.L. Brubaker & Y. Anini Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2 Can J Physiol Pharmacol 81 2003 1005-1012
18. Q. Xiao R.P. Boushey D.J. Drucker et al. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans Gastroenterology 117 1999 99-105
19. T. Vilsboll T. Krarup C.F. Deacon et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 50 2001 609-613
20. C. Hermann R. Goke G. Richter et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients Digestion 56 1995 117-126
21. J.N. Roberge & P.L. Brubaker Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients Endocrinology 128 1991 3169-3174
22. T.J. Kieffer C.H.S. McIntosh & R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585-3596
23. W. Tavares D.J. Drucker & P.L. Brubaker Enzymatic and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in the rat Am J Physiol 278 1999 E134-E139
24. B. Hartmann M.B. Harr P.B. Jeppesen et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans J Clin Endocrinol Metab 85 2000 2884-2888
25. R. Mentlein Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul Pept 85 1999 9-24
26. L. Hansen C.F. Deacon C. Orskov et al. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine Endocrinology 140 1999 5356-5363
27. C. Ruiz-Grande J. Pintado C. Alarcon et al. Renal catabolism of human glucagon-like peptides 1 and 2 Can J Physiol Pharmacol 68 1990 1568-1573
28. C. Orskov J. Andreasen & J.J. Holst All products of proglucagon are elevated in plasma from uremic patients J Clin Endocrinol Metab 74 1992 379-384
29. J.J. Meier M.A. Nauck D. Kranz et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects Diabetes 53 2004 654-662
30. B. Kreymann G. Williams M.A. Ghatei et al. Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300-1304
31. S. Mojsov G.C. Weir & J.F. Habener Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas J Clin Invest 79 1987 616-619
32. J.J. Holst C. Orskov O.V. Nielsen et al. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut FEBS Lett 211 1987 169-174
33. J. Gromada K. Bokvist W.G. Ding et al. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling Diabetes 47 1998 57-65
34. P.E. MacDonald X. Wang F. Xia et al. Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways J Biol Chem 278 2003 52446-52453
35. J. Gromada J.J. Holst & P. Rorsman Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1 Pflugers Arch 435 1998 583-594
36. G. Kang J.W. Joseph O.G. Chepurny et al. Epac-selective cAMP analog 8-pCPT-2′-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells J Biol Chem 278 2003 8279-8285
37. D.J. Drucker J. Philippe S. Mojsov et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line Proc Natl Acad Sci USA 84 1987 3434-3438
38. H-C. Fehmann & J.F. Habener Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells Endocrinology 130 1992 159-166
39. C.F. Deacon L. Pridal L. Klarskov et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig Am J Physiol 271 1996 E458-E464
40. B. Balkan & X. Li Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms Am J Physiol Regul Integr Comp Physiol 279 2000 R1449-R1454
41. B. Ahren Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice Am J Physiol Regul Integr Comp Physiol 286 2004 R269-R272
42. W. Moritz C.A. Leech J. Ferrer et al. Regulated expression of adenosine triphosphate-sensitive potassium channel subunits in pancreatic beta-cells Endocrinology 142 2001 129-138
43. G.G. Holz W.M. Kuhtreiber & J.F. Habener Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) Nature 361 1993 362-365
44. M.M. Byrne K. Gliem U. Wank et al. Glucagon-like peptide-1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance Diabetes 47 1998 1259-1265
45. Y. Wang R. Perfetti N.H. Greig et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats J Clin Invest 99 1997 2883-2889
46. Y. Wang J.M. Egan M. Raygada et al. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells Endocrinology 136 1995 4910-4917
47. T. Matsuyama R. Komatsu M. Namba et al. Glucagon-like peptide-1 (7-36) amide: A potent glucagonostatic and insulinotropic hormone Diabetes Res Clin Pract 5 1988 281-284
48. R.S. Heller T.J. Kieffer & J.F. Habener Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas Diabetes 46 1997 785-791
49. E. Samols S. Bonner-Weir & G.C. Weir Intra-islet insulin-glucagon-somatostatin relationships Clin Endocrinol Metab 15 1986 33-58
50. A. Wettergren B. Schjoldager P.E. Mortensen et al. Effect of GLP-1 on gastric motility and gastric and pancreatic secretion in man Digestion 54 1993 384-385
51. T. Tolessa M. Gutniak J.J. Holst et al. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: Effect mediated through central or enteric nervous mechanisms Dig Dis Sci 43 1998 2284-2290
52. N. Imeryuz B.C. Yegen A. Bozkurt et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms Am J Physiol 273 1997 G920-G927
53. M. Morales M.I. Lopez-Delgado A. Alcantara et al. Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats Diabetes 46 1997 1264-1269
54. J.M. Egan C. Montrose-Rafizadeh Y. Wang et al. Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: One of several potential extrapancreatic sites of GLP-1 action Endocrinology 135 1994 2070-2075
55. H. Miki M. Namba T. Nishimura et al. Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes Biochim Biophys Acta 1312 1996 132-136
56. C. Furnsinn K. Ebner & W. Waldhausl Failure of GLP-1 (7-36) amide to affect glycogenesis in rat skeletal muscle Diabetologia 38 1995 864-867
57. Y. Nakagawa K. Kawai H. Suzuki et al. Glucagon-like peptide-1(7-36)amide and glycogen synthesis in the liver Diabetologia 39 1996 1241-1242
58. D.A. D'alessio S.E. Kahn C.R. Leusner et al. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal J Clin Invest 93 1994 2263-2266
59. G.S. Meneilly C.H. McIntosh R.A. Pederson et al. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes Diabetes Care 24 2001 1951-1956
60. J.M. Egan G.S. Meneilly J.F. Habener et al. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state J Clin Endocrinol Metab 87 2002 3768-3773
61. L. Orskov J.J. Holst J. Moller et al. GLP-1 does not not acutely affect insulin sensitivity in healthy man Diabetologia 39 1996 1227-1232
62. M. Toft-Nielsen S. Madsbad & J.J. Holst The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones Diabetes 45 1996 552-556
63. H. Larsson J.J. Holst & B. Ahren Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans Acta Physiol Scand 160 1997 413-422
64. A.S. Ryan J.M. Egan J.F. Habener et al. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia J Clin Endocrinol Metab 83 1998 2399-2404
65. A. Vella P. Shah A.S. Reed et al. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans Diabetologia 45 2002 1410-1415
66. R.L. Prigeon S. Quddusi B. Paty et al. Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect Am J Physiol Endocrinol Metab 285 2003 E701-E707
67. B.P. Bullock R.S. Heller & J.F. Habener Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Endocrinology 137 1996 2968-2978
68. R.V. Campos Y.C. Lee & D.J. Drucker Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse Endocrinology 134 1994 2156-2164
69. P.F. Blackmore S. Mojsov J.H. Exton et al. Absence of insulinotropic glucagon-like peptide-I(7-37) receptors on isolated rat liver hepatocytes FEBS Lett 283 1991 7-10
70. I. Valverde E. Merida E. Delgado Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue Endocrinology 132 1993 75-79
71. M.B. Wheeler M. Lu J.S. Dillon et al. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C Endocrinology 133 1993 57-62
72. C. Montrose-Rafizadeh H. Yang Y. Wang et al. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes J Cell Physiol 172 1997 275-283
73. H. Yang J.M. Egan Y. Wang et al. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor Am J Physiol 275 1998 C675-C683
74. M.L. Villanueva-Penacarrillo E. Delgado M.A. Trapote et al. Glucagon-like peptide-1 binding to rat hepatic membranes J Endocrinol 146 1995 183-189
75. I. Idris D. Patiag S. Gray et al. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: Contrasting effects of GLP-1 Biochem Pharmacol 63 2002 993-996
76. M.A. Luque N. Gonzalez L. Marquez et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes J Endocrinol 173 2002 465-473
77. D.A. D'alessio R. Vogel R. Prigeon et al. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons J Clin Invest 97 1996 133-138
78. C.M. Edwards J.F. Todd M. Mahmoudi et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39 Diabetes 48 1999 86-93
79. Z. Wang R.M. Wang A.A. Owji et al. Glucagon-like peptide-1 is a physiological incretin in rat J Clin Invest 95 1995 417-421
80. L.A. Scrocchi T.J. Brown N. MaClusky et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene Nat Med 2 1996 1254-1258
81. J. Schirra K. Sturm P. Leicht et al. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans J Clin Invest 101 1998 1421-1430
82. S. Susini E. Roche M. Prentki et al. Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells Faseb J 12 1998 1173-1182
83. J. Buteau R. Roduit S. Susini et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells Diabetologia 42 1999 856-864
84. J. Zhou X. Wang M.A. Pineyro et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells Diabetes 48 1999 2358-2366
85. H. Hui C. Wright & R. Perfetti Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells Diabetes 50 2001 785-796
86. J. Zhou M.A. Pineyro X. Wang et al. Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: Involvement of PDX-1 and HNF3beta transcription factors J Cell Physiol 192 2002 304-314
87. J. Movassat G.M. Beattie A.D. Lopez et al. Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells J Clin Endocrinol Metab 87 2002 4775-4781
88. A.A. Hardikar X.Y. Wang L.J. Williams et al. Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin Endocrinology 143 2002 3505-3514
89. A. Edvell & P. Lindstrom Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea+/?) Endocrinology 140 1999 778-783
90. G. Xu D.A. Stoffers J.F. Habener et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270-2276
91. R. Perfetti J. Zhou M.E. Doyle et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats Endocrinology 141 2000 4600-4605
92. Q. Wang & P.L. Brubaker Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice Diabetologia 45 2002 1263-1273
93. C. Tourrel D. Bailbe M. Lacorne et al. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4 Diabetes 51 2002 1443-1452
94. D.A. Stoffers B.M. Desai D.D. DeLeon et al. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat Diabetes 52 2003 734-740
95. H. Hui A. Nourparvar X. Zhao et al. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway Endocrinology 144 2003 1444-1455
96. Y. Li T. Hansotia B. Yusta et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J Biol Chem 278 2003 471-478
97. L. Farilla A. Bulotta B. Hirshberg et al. GLP-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 144 2003 5149-5158
98. J. Buteau W. El-Assaad C.J. Rhodes et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity Diabetologia 47 2004 806-815
99. L. Farilla H. Hui C. Bertolotto et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats Endocrinology 143 2002 4397-4408
100. Z. Ling D. Wu Y. Zambre et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice Virchows Arch 438 2001 382-387
101. D.D. De Leon S. Deng R. Madani et al. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy Diabetes 52 2003 365-371
102. J. Buteau S. Foisy E. Joly et al. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor Diabetes 52 2003 124-132
103. D.A. Stoffers T.J. Kieffer M.A. Hussain et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas Diabetes 49 2000 741-748
104. R. Perfetti J. Zhou M.E. Doyle & 3 J.M. Egan Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats Endocrinology 141 2000 4600-4605
105. Y. Li T. Hansotia B. Yusta et al. Glucagon-like peptide-1 receptor signaling modulates B cell apoptosis J Biol Chem 278 2003 471-478
106. G. Kwon K.L. Pappan C.A. Marshall et al. cAMP dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in beta-cells J Biol Chem 279 2004 8938-8945
107. U.S. Jhala G. Canettieri R.A. Screaton et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2 Genes Dev 17 2003 1575-1580
108. A.E. Butler J. Janson S. Bonner-Weir et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 2003 102-110
109. M.D. Turton D. O'Shea I. Gunn et al. A role for glucagon-like peptide-1 in the central regulation of feeding Nature 379 1996 69-72
110. K. Meeran D. O'Shea C.M. Edwards et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat Endocrinology 140 1999 244-250
111. F. Rodriquez de Fonseca M. Navarro & E. Alvarez Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats Metabolism 49 2000 709-717
112. A. Flint A. Raben A. Astrup et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 101 1998 515-520
113. E. Naslund B. Barkeling N. King et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men Int J Obes Relat Metab Disord 23 1999 304-311
114. J.P. Gutzwiller J. Drewe B. Goke et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 Am J Physiol 276 1999 R1541-R1544
115. P.J. Larsen M. Tang-Christensen & D.S. Jessop Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat Endocrinology 138 1997 4445-4455
116. L. Rinaman Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus Am J Physiol 277 1999 R582-R590
117. L. Rinaman A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia Am J Physiol 277 1999 R1537-R1540
118. R.J. Seeley K. Blake P.A. Rushing et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride J Neurosci 20 2000 1616-1621
119. R. Goke P.J. Larsen J.D. Mikkelsen et al. Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites Eur J Neurosci 7 1995 2294-2300
120. J.C. Calvo B. Yusta F. Mora et al. Structural characterization by affinity cross-linking of glucagon-like peptide-1(7-36)amide receptor in rat brain J Neurochem 64 1995 299-306
121. J.J. Meier B. Gallwitz W.E. Schmidt et al. Glucagon-like peptide 1 as a regulator of food intake and body weight: Therapeutic perspectives Eur J Pharmacol 440 2002 269-279
122. C. Orskov S.S. Poulsen M. Moller et al. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I Diabetes 45 1996 832-835
123. C.M. Edwards A.V. Edwards & S.R. Bloom Cardiovascular and pancreatic endocrine responses to glucagon-like peptide-1(7-36) amide in the conscious calf Exp Physiol 82 1997 709-716
124. J.M. Barragan J. Eng R. Rodriguez et al. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats Am J Physiol 277 1999 E784-E791
125. D.F. Cechetto Central representation of visceral function Fed Proc 46 1987 17-23
126. A.V. Ferguson The area postrema: A cardiovascular control centre at the blood-brain interface? Can J Physiol Pharmacol 69 1991 1026-1034
127. Y. Wei & S. Mojsov Tissue-specific expression of the human receptor for glucagon-like peptide 1: Brain, heart and pancreatic forms have the same deduced amino acid sequences FEBS Lett 358 1995 219-224
128. H. Yamamoto C.E. Lee J.N. Marcus et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons J Clin Invest 110 2002 43-52
129. R. Gros X. You L.L. Baggio et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor Endocrinology 144 2003 2242-2252
130. M.B. Toft-Nielsen S. Madsbad & J.J. Holst Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients Diabetes Care 22 1999 1137-1143
131. C.M. Edwards S.A. Stanley R. Davis et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab 281 2001 E155-E161
132. M.S. Fineman T.A. Bicsak L.Z. Shen et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes Diabetes Care 26 2003 2370-2377
133. M. Yu C. Moreno & K.M. Hoagland Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats J Hypertens 21 2003 1125-1135
134. J.P. Gutzwiller S. Tschopp A. Bock et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men J Clin Endocrinol Metab 89 2004 3055-3061
135. L.A. Nikolaidis S. Mankad G.G. Sokos et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962-965
136. T. Perry D.K. Lahiri D. Chen et al. A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells J Pharmacol Exp Ther 300 2002 958-966
137. T. Perry N.J. Haughey M.P. Mattson et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4 J Pharmacol Exp Ther 302 2002 881-888
138. M.J. During L. Cao D.S. Zuzga et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection Nat Med 9 2003 1173-1179
139. T. Perry & N.H. Greig The glucagon-like peptides: A double-edged therapeutic sword? Trends Pharmacol Sci 24 2003 377-383
140. J. Oka E. Suzuki & Y. Kondo Endogenous GLP-1 is involved in beta-amyloid protein-induced memory impairment and hippocampal neuronal death in rats Brain Res 878 2000 194-198
141. M. Zander S. Madsbad J.L. Madsen et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study Lancet 359 2002 824-830
142. W.O. Creutzfeld N. Kleine B. Willms et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients Diabetes Care 19 1996 580-586
143. J. Dupre M.T. Behme I.M. Hramiak et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM Diabetes 44 1995 626-630
144. J. Dupre M.T. Behme I.M. Hramiak et al. Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM Diabetes Care 20 1997 381-384
145. G.C. Weir S. Mojsov G.K. Hendrick et al. Glucagonlike peptide I (7-37) actions on endocrine pancreas Diabetes 38 1989 338-342
146. R. Goke B. Wagner H.C. Fehmann et al. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas Res Exp Med 193 1993 97-103
147. M.A. Nauck M.M. Heimesaat K. Behle et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers J Clin Endocrinol Metab 87 2002 1239-1246
148. A.A. Vaag J.J. Holst A. Volund et al. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins Eur J Endocrinol 135 1996 425-432
149. J. Eng W.A. Kleinman L. Singh et al. Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom J Biol Chem 267 1992 7402-7405
150. O.G. Kolterman J.B. Buse M.S. Fineman et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 88 2003 3082-3089
151. J.M. Egan G.S. Meneilly & D. Elahi Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes Am J Physiol Endocrinol Metab 284 2003 E1072-E1079
152. C.B. Juhl M. Hollingdal J. Sturis et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes Diabetes 51 2002 424-429
153. K.B. Degn C.B. Juhl J. Sturis et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 2004 1187-1194
154. S. Madsbad O. Schmitz J. Ranstam et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial Diabetes Care 27 2004 1335-1342
155. J.G. Kim L.L. Baggio D.P. Bridon et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo Diabetes 52 2003 751-759
156. D. Marguet L. Baggio & T. Kobayashi Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc Natl Acad Sci USA 97 2000 6874-6879
157. S.L. Conarello Z. Li J. Ronan et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc Natl Acad Sci USA 100 2003 6825-6830
158. B. Ahren J.J. Holst H. Martensson et al. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice Eur J Pharmacol 404 2000 239-245
159. R.A. Pederson H.A. White D. Schlenzig et al. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide Diabetes 47 1998 1253-1258
160. C.F. Deacon T.E. Hughes & J.J. Holst Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig Diabetes 47 1998 764-769
161. B. Balkan L. Kwasnik R. Miserendino et al. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats Diabetologia 42 1999 1324-1331
162. R.P. Pauly H.U. Demuth F. Rosche et al. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide Metabolism 48 1999 385-389
163. J.A. Pospisilik J. Martin T. Doty et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 52 2003 741-750
164. J.A. Pospisilik S.G. Stafford H.U. Demuth et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats Diabetes 51 2002 943-950
165. J.A. Pospisilik S.G. Stafford H.U. Demuth et al. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: A euglycemic-hyperinsulinemic clamp study Diabetes 51 2002 2677-2683
166. T. Hoffman K. Glund C.H.S. McIntosh et al. DPPIV inhibition as treatment of type II diabetes In: S. Mizutani (Eds.) Cell-surface Aminopeptidases: Basic and Clinical Aspects 2001 Elsevier Amsterdam 381-387
167. B. Ahren E. Simonsson H. Larsson et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 2002 869-875
168. B. Ahren M. Landin-Olsson & P.A. Jansson Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 89 2004 2078-2084
169. B. Fleischer CD26: A surface protease involved in T-cell activation Immunol Today 15 1994 180-184
170. M.H. Gleeson S.R. Bloom J.M. Polak et al. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function Gut 12 1971 773-782
171. D.J. Drucker P. Ehrlich & S.L. Asa Induction of intestinal epithelial proliferation by glucagon-like peptide 2 Proc Natl Acad Sci USA 93 1996 7911-7916
172. M. Gregor H. Menge R. Stosselet al. Effect of monoclonal antibodies to
173. D.M. Irwin Molecular evolution of proglucagon Regul Pept 98 2001 1-12
174. D.J. Drucker L. Deforest & P.L. Brubaker Intestinal response to growth factors administered alone or in combination with h[Gly2]-glucagon-like peptide 2 Am J Physiol 273 1997 G1252-G1262
175. D.J. Drucker Q. Shi & A. Crivici Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV Nat Biotechnol 15 1997 673-677
176. Y. Kato D. Yu & M.Z. Schwartz Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo J Pediatr Surg 34 1999 18-20
177. T.J. Kieffer C.H. McIntosh & R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585-3596
178. B. Hartmann J. Thulesen H. Kissow et al. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice Endocrinology 141 2000 4013-4020
179. C.H. Tsai M. Hill S.L. Asa et al. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice Am J Physiol 273 1997 E77-E84
180. C.H. Tsai M. Hill & D.J. Drucker Biological determinants of intestinotrophic properties of GLP-2 in vivo Am J Physiol 272 1997 G662-G668
181. W.T. Chance T. Foley-Nelson I. Thomas et al. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2 Am J Physiol 273 1997 G559-G563
182. P.A. Kitchen A.J. Fitzgerald R.A. Goodlad et al. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression Am J Physiol Gastrointest Liver Physiol 278 2000 G425-G428
183. M.A. Ghatei R.A. Goodlad S. Taheri et al. Proglucagon-derived peptides in intestinal epithelial proliferation: Glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats Dig Dis Sci 46 2001 1255-1263
184. W.T. Chance S. Sheriff T. Foley-Nelson et al. Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: Effects of glucagon-like peptide 2 Nutr Cancer 37 2000 215-222
185. K.D. Fischer S. Dhanvantari D.J. Drucker et al. Intestinal growth is associated with elevated levels of glucagon-like peptide-2 in diabetic rats Am J Physiol 273 1997 E815-E820
186. B. Hartmann J. Thulesen K.J. Hare et al. Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats Regul Pept 105 2002 173-179
187. M.E. Hill S.L. Asa & D.J. Drucker Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription Mol Endocrinol 13 1999 1474-1486
188. Y.M. Petersen D.G. Burrin & P.T. Sangild GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs Am J Physiol Regul Integr Comp Physiol 281 2001 R1986-R1993
189. J. Lovshin B. Yusta I. Iliopoulos et al. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine Endocrinology 141 2000 4194-4201
190. R.P. Boushey B. Yusta & D.J. Drucker Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis Am J Physiol 277 1999 E937-E947
191. K. Alavi M.Z. Schwartz J.P. Palazzo et al. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2 J Pediatr Surg 35 2000 847-851
192. K. Ljungmann B. Hartmann P. Kissmeyer-Nielsen et al. Time-dependent intestinal adaptation and GLP-2 alterations after small bowel resection in rats Am J Physiol Gastrointest Liver Physiol 281 2001 G779-G785
193. E.M. Dahly M.B. Gillingham Z. Guo et al. Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection Am J Physiol Gastrointest Liver Physiol 284 2003 G670-G682
194. R.B. Scott D. Kirk W.K. MacNaughton et al. GLP-2 augments the adaptive response to massive intestinal resection in rat Am J Physiol 275 1998 G911-G921
195. W.T. Chance S. Sheriff F. McCarter et al. Glucagon-like peptide-2 stimulates gut mucosal growth and immune response in burned rats J Burn Care Rehabil 22 2001 136-143
196. R. Prasad K. Alavi & M.Z. Schwartz Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion J Pediatr Surg 35 2000 357-359
197. R. Prasad K. Alavi & M.Z. Schwartz GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion J Pediatr Surg 36 2001 570-572
198. A. Tavakkolizadeh R. Shen P. Abraham et al. Glucagonlike peptide 2 (glp-2) promotes intestinal recovery following chemotherapy-induced enteritis Curr Surg 57 2000 502
199. R.P. Boushey B. Yusta & D.J. Drucker Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor Cancer Res 61 2001 687-693
200. D.J. Drucker B. Yusta R.P. Boushey et al. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis Am J Physiol 276 1999 G79-G91
201. D.G. Munroe A.K. Gupta F. Kooshesh et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2 Proc Natl Acad Sci USA 96 1999 1569-1573
202. K.E. Mayo L.J. Miller D. Bataille et al. International union of pharmacology. XXXV. The glucagon receptor family Pharmacol Rev 55 2003 167-194
203. B. Yusta R. Somwar F. Wang et al. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor J Biol Chem 274 1999 30459-30467
204. E. Velazquez J.M. Ruiz-Albusac & E. Blazquez Glucagon-like peptide-2 stimulates the proliferation of cultured rat astrocytes Eur J Biochem 270 2003 3001-3009
205. B. Yusta L. Huang D. Munroe et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents Gastroenterology 119 2000 744-755
206. M. Bjerknes & H. Cheng Modulation of specific intestinal epithelial progenitors by enteric neurons Proc Natl Acad Sci USA 98 2001 12497-12502
207. D.G. Burrin B. Stoll R. Jiang et al. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis Am J Physiol Gastrointest Liver Physiol 279 2000 G1249-G1256
208. B. Yusta R.P. Boushey & D.J. Drucker The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway J Biol Chem 275 2000 35345-35352
209. B. Yusta J. Estall & D.J. Drucker GLP-2 receptor activation engages Bad and glycogen synthase kinase 3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase J Biol Chem 277 2002 24896-24906
210. P.B. Jeppesen B. Hartmann J. Thulesen et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon Gastroenterology 120 2001 806-815